CELU Stock Analysis: Buy, Sell, or Hold?
CELU - Celularity Inc. Class A Common Stock
$1.58
-0.52 (-24.76%)
▼
5d:
+97.49%
30d:
+132.35%
90d:
+56.44%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Sep 04, 2026
4d
Get Alerted When CELU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CELU is 43.6% above its trading range ($1.10). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CELU is 43.6% above its trading range ($1.10). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CELU is currently trading at $1.58, which is considered extended relative to its 30-day fair value range of $0.52 to $1.10.
Technical Outlook: Technically, CELU is in a downtrend. Immediate support is located at $0.68, while resistance sits at $2.55. Short-term momentum is weak, with the stock down 24.8% recently.
Market Sentiment: CELU scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.50 (+58.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CELU is in a downtrend. Immediate support is located at $0.68, while resistance sits at $2.55. Short-term momentum is weak, with the stock down 24.8% recently.
Market Sentiment: CELU scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.50 (+58.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.52 -
$1.10
Company Quality Score
39/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
5.3%
Protect Your Profits
Holding CELU? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+43.6% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BEARISH: Downward momentum (-24.8%)
- BULLISH: Trading 58.2% below Wall St target ($2.50)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.52 -
$1.10
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$2.55
Current Trend
Downtrend
Technical data as of
Aug 28, 2026
Fundamental Context
Wall Street Target
$2.50
(+58.2%)
Revenue Growth (YoY)
-77.4%
Earnings Growth (YoY)
-61.3%
Share & Embed Analysis
Last updated: August 30, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CELU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 49 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 57 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 60 BUY |
Advanced CELU Option Strategies
Professional options setups generated by AI based on today's CELU price and gamma walls.
